Condition: Cholangiocarcinoma Non-resectable · Non-metastatic · Sponsor: University Hospital, Montpellier
We hypothesized that intra-arterial gemcitabine/oxaliplatin administered as second-line treatment could strongly improve objective response rate at 4 months after inclusion in patient with non-metastatic unresectable intra-hepatic cholangiocarcinoma.
This description comes directly from the study's public registry record.
Chloé Guillot · +33467337327 · chloe-guillot@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| Amiens University Hospital | Amiens, France | Recruiting |
| Angers University Hospital | Angers, France | Recruiting |
| Bordeaux University Hospital | Bordeaux, France | Recruiting |
| Centre Georges François Leclerc | Dijon, France | Recruiting |
| Uhmontpellier | Montpellier, France | Recruiting |
| Hôpital Européen Georges Pompidou | Paris, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03364530